Learn more about whether Globus Medical, Inc. or LeMaitre Vascular, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Globus Medical, Inc. shines with strong Q4 results & Nevro acquisition, boosting its market position. Click here to find out ...

Analysts expect Penumbra to report an earnings per share (EPS) of $0.67. The announcement from Penumbra is eagerly ...

Investors need to pay close attention to Globus Medical (GMED) stock based on the movements in the options market lately.

Globus Medical, Inc. (NYSE: GMED) will release its first-quarter 2025 financial results on Thursday, May 8, 2025, after ...

Trupanion, Inc. (Nasdaq: TRUP), a leader in medical insurance for cats and dogs, announced today it will report financial results for its 2025 first quarter after the market closes on Thursday, May 1, ...

Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Globus Medical (GMED – Research Report) on April 15 and set a price target ...

BTIG lowered the firm’s price target on Globus Medical (GMED) to $88 from $94 and keeps a Buy rating on the shares as part of a broader ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.